CROSBY Research – Crosby Bi-noculars (Bi-weekly Issue 80)

2 Jun 2025

• Based in Hong Kong, SinoMab is a pioneering biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of therapeutics for immunological diseases, with a primary focus on monoclonal antibody (mAb)-based biologics. SM17 is a global, first-in-class humanized mAb designed to target the IL-25 receptor. With the potential to treat atopic dermatitis (AD), asthma, idiopathic pulmonary fibrosis (IPF), and other immunological disorders, SM17 represents a groundbreaking advancement in therapeutic development.